Therapeutic strategy for HER-2-positive advanced breast cancer
10.3969/j.issn.1000-8179.2016.10.237
- VernacularTitle:HER-2阳性晚期乳腺癌治疗策略
- Author:
Jing SUN
;
Pin ZHANG
- Publication Type:Journal Article
- Keywords:
HER-2-positive;
advanced breast cancer;
therapeutic strategy;
clinical trials;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2016;43(10):412-417
- CountryChina
- Language:Chinese
-
Abstract:
Patients with HER-2-positive advanced breast cancer were associated with poor prognosis. Meanwhile, HER-2-targeted ther-apy has dramatically improved survival and prognosis among breast cancer patients. Over the years, multiple HER-2-targeting drugs stepped into clinical practice, and the targeted agents are now considered as the standard of care in the first-line setting and beyond. This review basically summarizes the importance of HER-2-targeted therapy, the significance of the clinical trial results, and the clinical practice guidelines for the management of patients with HER-2-positive advanced breast cancer.
